Midlife Serum Cholesterol and Increased Risk of Alzheimer’s and Vascular Dementia Three Decades Later
Open accessThe DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
Aims: To investigate midlife cholesterol in relation to Alzheimer’s disease (AD) and vascular dementia (VaD) in a large multiethnic cohort of women and men. Methods: The Kaiser Permanente Northern California Medical Group (healthcare delivery organization) formed the database for this study. The 9,844 participants underwent detailed health evaluations during 1964–1973 at ages 40–45 years; they were still members of the health plan in 1994. AD and VaD were ascertained by medical records between 1 January 1994 and 1 June 2007. Cox proportional hazards models – adjusted for age, education, race/ethnic group, sex, midlife diabetes, hypertension, BMI and late-life stroke – were conducted. Results: In total, 469 participants had AD and 127 had VaD. With desirable cholesterol levels (<200 mg/dl) as a reference, hazard ratios (HR) and 95% CI for AD were 1.23 (0.97–1.55) and 1.57 (1.23–2.01) for borderline (200–239 mg/dl) and high cholesterol (≥240 mg/dl), respectively. HR and 95% CI for VaD were 1.50 (1.01–2.23) for borderline and 1.26 (0.82–1.96) for high cholesterol. Further analyses for AD (cholesterol quartiles, 1st quartile reference) indicated that cholesterol levels >220 mg/dl were a significant risk factor: HR were 1.31 (1.01–1.71; 3rd quartile, 221–248 mg/dl) and 1.58 (1.22–2.06; 4th quartile, 249–500 mg/dl). Conclusion: Midlife serum total cholesterol was associated with an increased risk of AD and VaD. Even moderately elevated cholesterol increased dementia risk. Dementia risk factors need to be addressed as early as midlife, before underlying disease(s) or symptoms appear.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Findings in late-life cohorts vary, with some finding higher levels of cholesterol associated with a lower risk356 and others finding a higher risk for VaD.357”
In the citing paper
“there are several controllable risk factors including obesity [156,157], hyperlipidemia [158,159], hypertension [160,161,162,163], type 2 diabetes [164,165,166,167], and sedentary lifestyle [168] that can be addressed in an effort to decrease the risk of developing AD.”
From Mitochondrial Oxidative and Nitrosative Stress and Alzheimer Disease (2020) · cites this paper as [158]
In the citing paper
“Obesity,71–73 dyslipidemia,74–77 and high BP78,79 are also major contributors to vascular brain health.”
From Defining Optimal Brain Health in Adults: A Presidential Advisory From the American Heart Association/American Stroke Association (2017) · cites this paper as [75]
Citations
Cites
Detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III)
Grundy, S. M., Becker, D. M., Clark, L. T., Cooper, R., Denke, M. A., Howard, J. L., Hunninghake, D. B., Illingworth, D. R., Luepker, R. V., McBride, P. E., et al. (2002) · Civil War Book Review · Cited by 12,198
Hachinski, V., Iadecola, C., Petersen, R. C., Breteler, M. M., Nyenhuis, D. L., Black, S. E., Powers, W. J., DeCarli, C., Merino, J. G., Kalaria, R. N., et al. (2006) · Stroke · doi:10.1161/01.str.0000237236.88823.47 · Cited by 1,722 · cited 1×
“significantly increased the risk of developing VaD 3 decades later. High cholesterol levels (≥240 mg/dl) tended to increase VaD risk as well, but the association did not reach statistical significance. One reason for this could be the small sample size of VaD (127 persons in total, 39 with high cholesterol).VaD repres…”
BackgroundKrieger, N. (1992) · American Journal of Public Health · doi:10.2105/ajph.82.5.703 · Cited by 1,654 · cited 1×
“The present study investigates further the cholesterol-dementia relationship by focusing on the 2 main dementia subtypes, AD and vascular dementia (VaD), in a larger Kaiser Permanente cohort with updated follow-up information. We also examined the full range of cholesterol values (not just high cholesterol, >240 mg/dl…”
BackgroundMidlife cardiovascular risk factors and risk of dementia in late life
Whitmer, R. A., Sidney, S., Selby, J., Johnston, S. C., & Yaffe, K. (2005) · Neurology · doi:10.1212/01.wnl.0000149519.47454.f2 · Cited by 1,238 · cited 1×
“High midlife cholesterol has previously been shown to be a risk factor for dementia in the multiethnic cohort of women and men from the Kaiser Permanente Medical Care Program of Northern California [”
BackgroundSelf-citationKivipelto, M., Ngandu, T., Laatikainen, T., Winblad, B., Soininen, H., & Tuomilehto, J. (2006) · The Lancet Neurology · doi:10.1016/s1474-4422(06)70537-3 · Cited by 1,126 · cited 1×
“Although our cohort does not include persons with mixed dementia as recognized by ICD-9 CM, the concomitant presence of neurodegenerative and vascular pathologies in a portion of the sample cannot be excluded. Clinical Significance and ConclusionsPhysicians tend to confine AD and VaD to geriatric age borders, and addr…”
ResultSelf-citationSerum Total Cholesterol, Apolipoprotein E {FC12}e4 Allele, and Alzheimer’s Disease
Notkola, I.-L., Sulkava, R., Pekkanen, J., Erkinjuntti, T., Ehnholm, C., Kivinen, P., Tuomilehto, J., & Nissinen, A. (1998) · Neuroepidemiology · doi:10.1159/000026149 · Cited by 669
Kivipelto, M., Helkala, E.-L., Laakso, M. P., Hänninen, T., Hallikainen, M., Alhainen, K., Iivonen, S., Mannermaa, A., Tuomilehto, J., Nissinen, A., et al. (2002) · Annals of Internal Medicine · doi:10.7326/0003-4819-137-3-200208060-00006 · Cited by 645
Self-citationIribarren, C., Sidney, S., Sternfeld, B., & Browner, W. S. (2000) · JAMA · doi:10.1001/jama.283.21.2810 · Cited by 482
Kalmijn, S., Foley, D., White, L., Burchfiel, C. M., Curb, J. D., Petrovitch, H., Ross, G. W., Havlik, R. J., & Launer, L. J. (2000) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.20.10.2255 · Cited by 417 · cited 1×
“but no association was observed in the Honolulu Asia Aging Study (HAAS) or Framingham study [”
BackgroundCrossing the barrier: oxysterols as cholesterol transporters and metabolic modulators in the brain
BJÖRKHEM, I. (2006) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2006.01725.x · Cited by 381
Cited by
Items 501–553 of 553
Molecular Basis of Membrane Pore Formation by Amyloid Beta Peptide
Kandel, N. (2019) · STARS (University of Central Florida)
Current awareness in geriatric psychiatry
(2010) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.2390
Đukić, N., Nešković, M., Ševković, M., & Radak, Đ. (2016) · Medicinska istrazivanja · doi:10.5937/medist1602023q
(2016) · Elsevier eBooks · doi:10.1016/b978-0-12-804538-1.00036-5
Matthews, B. R. (2016) · Cambridge University Press eBooks · doi:10.1017/9781139924771.009
Potential Role of Hypercoagulation in the Onset and Progression of Obesity Induced NeurodegenerationPreprint
Khan, S. I., Hasan, N., Anwar, L., Khan, S., Akhtar, M., Akhtar, M., & Najmi, A. K. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.4159332
Influence of cardiovascular risk factors on the cognitive functions of schizophrenia patients
Voronko, E. A., Shevchenko, E. V., Рачкаускас, Г. С., Kondufor, O. V., Kolesnikov, D. A., Yatsenko, D. A., Eroshenko, S. Y., & Lisitskaya, S. V. (2022) · Vestnik nevrologii psihiatrii i nejrohirurgii (Bulletin of Neurology Psychiatry and Neurosurgery) · doi:10.33920/med-01-2211-02
The Measurement of Lipids and Lipoproteins in Behavioral Medicine Research
Stoney, C. M. (2022) · Springer eBooks · doi:10.1007/978-0-387-85960-6_33
Singh, K., Nandha, R., & Prashar, S. (2022) · International Journal of Community Medicine and Public Health · doi:10.18203/2394-6040.ijcmph20223547 · Cited by 1
Tsang, C. C. S., Zhang, X., Barenie, R. E., Cernasev, A., Miller, N. A., Wan, J. Y., Tsao, J. W., & Wang, J. (2023) · Medicine · doi:10.1097/md.0000000000033641
“[6] Furthermore, in a retrospective cohort study among patients of Kaiser Permanente in North Carolina, Solomon et al[7] found that midlife cholesterol level was associated with a rise in Alzheimer’s disease risk in later life.”
BackgroundRodriguez, S., Thiruchelvi, R., Thenmozhi, A. J., Cosio, D. S., Shamaladevi, N., Hussain, H., Natarajan, S., Paidas, M. J., & Jayakumar, A. R. (2023) · Nutritional neurosciences · doi:10.1007/978-981-99-0677-2_5
Combination therapies delay cognitive decline over 10 years in Alzheimer’s NACC participantsPreprint
Shang, Y., Torrandell‐Haro, G., Vitali, F., & Brinton, R. D. (2024) · medRxiv · doi:10.1101/2024.01.31.24301055
Coping strategies in patients with schizophrenia and concomitant chronic cardiovascular diseases
Рачкаускас, Г. С., Kondufor, O. V., Kolesnikov, D. A., Kizimenko, S. V., Kardash, M. I., Kharkovskiy, V. E., Kharkovskaya, M. A., & Markaryan, G. A. (2024) · Vestnik nevrologii psihiatrii i nejrohirurgii (Bulletin of Neurology Psychiatry and Neurosurgery) · doi:10.33920/med-01-2404-09
Exploring the Intersection of Dementia and Myocardial Infarction: Vascular Perspectives
Goyal, A., Ekelmans, A., & Frishman, W. H. (2024) · Cardiology in Review · doi:10.1097/crd.0000000000000718
Alanko, V., Eroli, F., Végvári, Á., Solomon, A., Hartmann, T., Nilsson, P., Kivipelto, M., Maioli, S., & Matton, A. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.09.23.614418
“Vascular risk monitoring is an essential part of the FINGER model as previous research has demonstrated the importance of cardiovascular diseases as risk factors for dementia (Hughes et al., 2020; Solomon et al., 2009).”
MethodSelf-citationAyandeyi, K., Shaha, S., & Chilaka, M. A. (2024) · Journal of Family Medicine and Health Care · doi:10.11648/j.jfmhc.20241003.14
Zhang, Y., Yaseri, A. F., Kulshreshtha, A., Crump, C., & Wei, J. (2024) · Preventive Medicine · doi:10.1016/j.ypmed.2024.108208
Elgardawi, M. M., Othman, K. A., Mesallati, A., Abdelmalik, A. M., & Idrise, D. W. (2025) · Libyan Journal of Science &Technology · doi:10.37376/ljst.v14i2.7205
Zachara, R., de Carrillo, D. G., Właszczuk, A., Gorzkowska, A., Mazur, W., & Jędrzejowska–Szypułka, H. (2025) · Neurology International · doi:10.3390/neurolint17110180
“In the study by Solomon et al., elevated total cholesterol levels in middle age increased the risk of developing AD and vascular dementia [55].”
Rodrigues, M. S., do Nascimento, N. B., Baumart, G. J., Schons, T., Padilha, A. P., Costa, M., Farias, H. R., Beber, L. C. C., Fróes, F. T., Peres, A. M., et al. (2025) · Molecular Neurobiology · doi:10.1007/s12035-025-05317-2
Alcohol use as a potential moderator of risk factors for Alzheimer's disease
Stelmokas, J. (2013) · CommonKnowledge Research Repository (Pacific University Oregon)
Jeong, S. H., Chung, S. J., Yoo, H. S., Jung, J. H., Baik, J. S., Sohn, Y. H., & Lee, P. H. (2024) · Figshare · doi:10.6084/m9.figshare.25123992
Lerner, A. J., Arnold, S. E., Maxfield, E., Koenig, A., Toth, M. E., Fortin, B. M., Mast, N., Trombetta, B. A., Denker, J. A., Pieper, A. A., et al. (2023) · Figshare · doi:10.6084/m9.figshare.22613698
Bem, A. F. D., Farias, H. R., Engel, D. F., Brocardo, P. S., & de Oliveira, J. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-33841-0.00006-3
Messaoudi, S. A., Alsaleh, A. B., AlSalem, L. A., Rameshbabu, S., Kumar, S., Assidi, M., Ouanes, K., Chayeb, V. A., Zitouni, H., & Almawi, W. Y. (2026) · Journal of Alzheimer s Disease · doi:10.1177/13872877261427358
“28,30 Higher educational attainment was associated with a lower prevalence of dementia, supporting the concept of cognitive reserve delaying the clinical manifestation of cognitive impairment.”
An Integrated Approach on Vascular Cognitive Impairment
Jianu, D. C., Jianu, S. N., Bora, B. I., Munteanu, G., Bertici, R.-A., Dan, T. F., & Petrică, L. (2026) · IntechOpen eBooks · doi:10.5772/intechopen.1014841
Betat, A., dos Santos, V., de Oliveira, C. G. A., Alflen, L., Ferreira, C. F., Izídio, G. S., & Lataro, R. M. (2026) · Journal of Hypertension · doi:10.1097/hjh.0000000000004277
Hanbouch, L. (2017) · theses.fr (ABES) · doi:10.70675/c4d2c894zf69dz4ae4z9ab1zf4135d0efa12
Enette, L. (2019) · theses.fr (ABES) · doi:10.70675/1ad1a02ez8eebz4234z9bdfzf1e991390f85
Marqueurs périphériques de l'inflammation et déclin cognitif au cours de la maladie d'Alzheimer
Julian, A. (2018) · theses.fr (ABES) · doi:10.70675/0f58e0a1z28d9z40b7z886fz752caf42c261
Lefèvre‐Arbogast, S. (2019) · theses.fr (ABES) · doi:10.70675/6915e632z663fz4caaz9c7az455ad25755da
Wagner, M. (2019) · theses.fr (ABES) · doi:10.70675/22404981zcf3cz47ffzbfb7z3ed36606f44e · Cited by 2
Léger-Charnay, E. (2019) · theses.fr (ABES) · doi:10.70675/72ca31b1zc2d8z41dbz9f66zcbe3f38a8b4a
“Même si toutes les études épidémiologiques ne sont pas concordantes, plusieurs suggèrent que l’hypercholestérolémie prédispose à cette maladie (Pappolla et al. 2003, Kivipelto et al., 2001, Whitmer et al. 2005, Solomon et al., 2009).”
BackgroundStratégies de ré-analyse d'un essai de prévention du déclin des fonctions cognitives non concluant
Bougel, C. (2020) · theses.fr (ABES) · doi:10.70675/9f920116z1378z4232z8590z40226aa8975f
Sáez-González, L., Martínez, L. A., García-García, C., Abellán, G. B., de Lara, J. A. C., Martinez-Garcia, R. M., & Castro-Vázquez, L. (2026) · BMC Public Health · doi:10.1186/s12889-026-27246-y
Bürger, M. E., Pase, C. S., & Rossato, D. R. (2026) · Advances in neurotoxicology · doi:10.1016/bs.ant.2025.04.005
Prado-Lopes, N., Fagundes, D., Tavares, L., Santos, W., Barros, W. D. M., Moschen, H. T. S., Mortari, M. R., Goulart, J. T., Amato, A. A., de Oliveira, J., et al. (2026) · Biology of Sex Differences · doi:10.1186/s13293-026-00893-x
“Supporting this link, longitudinal population-based studies have shown that elevated cholesterol levels during midlife are associated with an increased risk of mild cognitive impairment (MCI) and vascular dementia later in life [10, 11].”
VASCULAR COGNITIVE IMPAIRMENT: RISK FACTORS, PREVENTION AND TREATMENT
Szarek, R., Kulka, K., Król, W., Kafara, Z., Kowalczyk, D., Lechowska, Z., Kafara, A., Koronczok-Matusiak, J., Michta, K., Strzałkowska, B., et al. (2026) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.2(50).2026.5302
Kearley, J., Rajagopal, C., LoParco, S., Bhaskara, M. R., Uddin, L. Q., Mišić, B., Einstein, G., Pilote, L., & Rajah, M. N. (2026) · Research Square · doi:10.21203/rs.3.rs-10157591/v1
Dhanasekara, C. S., Kahathuduwa, C. N., & Neugebauer, V. (2026) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2026.1836968
“…glucose-FBS), (Lin et al., 2023; Saczynski et al., 2008) lipid metabolism (triglycerides, high density lipoprotein-HDL), (Solomon et al., 2009a; Solomon et al., 2009b) nutritional status and adiposity [albumin, (Cui et al., 2024) body mass index-BMI, (Elias et al., 2005; Li et al., 2020),…”
Physical activity and metabolic syndrome in relation to incident dementia in UK biobank
Li, Y., Ren, X., Jiang, M., Yang, P., Jia, Y., Sun, L., Wang, R., Shi, M., Zheng, X., Zhu, Z., et al. (2026) · Nutrition & Metabolism · doi:10.1186/s12986-025-01058-0
Appiah, F., Simpong, D. L., Osei, G. N., Dogah, J., Marfo, E., Antwi, M. H., Donkor, D. M., Manu, K. S., & Bockarie, A. S. (2026) · Journal of Alzheimer s Disease Reports · doi:10.1177/25424823261475263
“16 Similarly, midlife hypercholesterolemia was associated with increased risk of both AD and VaD, 49 high-lighting the importance of lipid exposure during earlier stages of life.”
InfluentialElefante, C., Beatino, M. F., Marro, D., Coccoglioniti, A., Lazzerini, C., Pacini, A., Gasparyan, A., Caparrós, E., Petrozzi, L., Siciliano, G., et al. (2026) · Journal of Geriatric Psychiatry and Neurology · doi:10.1177/08919887261477071
Cochran, J. N., Pugh, J., Coleman, T., Kelley, W. V., Jamieson, P., Dunne, E., Smith, P., Chasteen, J., Jones, M., Turner, J., et al. (2026) · medRxiv · doi:10.64898/2026.09.19.26363495
GLP‐1R agonist semaglutide protects human forebrain organoids from cholesterol‐induced neurotoxicity
Yu, F., Xu, J., Hou, Y., Zheng, H., Guo, L., Khutsishvili, D., Hai, C., Xu, W., Chen, B., Wang, Z., et al. (2026) · Alzheimer s & Dementia · doi:10.1002/alz.71888
“16 Thus, aberrant cholesterol metabolism represents a common pathological denominator underlying both early neurodevelopmental defects and late-life cognitive decline.”
Cholesterol Metabolism and Oxidative Stress in Alzheimer’s Disease
Iuliano, L., & Leoni, V. (2013) · Oxidative stress in applied basic research and clinical practice · doi:10.1007/978-1-62703-598-9_9
Metadata
- Authors
- Solomon, A., Kivipelto, M., Wolozin, B., Zhou, J., & Whitmer, R. A.
- Affiliations
- University of Eastern Finland (FI)
- Boston University (US)
- Kaiser Permanente (US)
- Venue
- Dementia and Geriatric Cognitive Disorders
- Publisher
- S. Karger AG
- Published
- 2009
- Volume
- 28
- Issue
- 1
- Pages
- 75-80
- ISSN
- 1420-8008 (ISSN-L)
- 1421-9824
- PMC
- PMC2814023
- OpenAlex
- W2134458253
- Cited by
- 557
- References
- 22
- Citations by year
- 2026: 22 · 2025: 25 · 2024: 36 · 2023: 25 · 2022: 31 · 2021: 42 · 2020: 31 · 2019: 34 · 2018: 37 · 2017: 32 · 2016: 39 · 2015: 27 · 2014: 41 · 2013: 39 · 2012: 42
- FWCI
- 19.74
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- www.karger.com/Services/SiteLicenses (vor)
- www.karger.com/Services/SiteLicenses (tdm)
- Locations
- Dementia and Geriatric Cognitive Disorders (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Kaiser Permanente
- National Institute of Diabetes and Digestive and Kidney Diseases (K01DK066308, DK066308)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Keywords
- Alzheimer's disease, vascular dementia, dementia risk factors, total cholesterol, hypercholesterolemia, multi-ethnic cohort, men and women
- MeSH terms
- Adult, Aged, Alzheimer Disease, Cholesterol, Data Interpretation, Statistical, Female, Follow-Up Studies, Humans, Male, Middle Aged, Retrospective Studies, Socioeconomic Factors, Dementia, Vascular, Cohort Studies, Proportional Hazards Models, Risk Assessment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.